Summit Therapeutics Inc. (SMMT)
NASDAQ$19.29
Market Cap
$14.23B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
837 of 916
Rank in Industry
475 of 522
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
SMMT Insider Trading Activity
SMMT Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Related Transactions
No records found
About Summit Therapeutics Inc.
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae …
Insider Activity of Summit Therapeutics Inc.
Over the last 12 months, insiders at Summit Therapeutics Inc. have bought $0 and sold $0 worth of Summit Therapeutics Inc. stock.
On average, over the past 5 years, insiders at Summit Therapeutics Inc. have bought $156.93M and sold $321,463 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 80,321 shares for transaction amount of $298,594 was made by Zanganeh Mahkam (Chief Executive Officer) on 2024‑03‑27.
List of Insider Buy and Sell Transactions, Summit Therapeutics Inc.
| 2024-03-27 | Zanganeh Mahkam | Chief Executive Officer | 80,321 0.0113% | $3.72 | $298,594 | +378.13% | ||
| 2024-03-26 | Dhingra Ankur | Chief Financial Officer | 100,000 0.0143% | $3.75 | $375,000 | +378.07% | ||
| 2024-03-26 | Zanganeh Mahkam | Chief Executive Officer | 30,000 0.0043% | $3.75 | $112,500 | +378.07% | ||
| 2023-12-13 | Dhingra Ankur | Chief Financial Officer | 20,400 0.0027% | $2.17 | $44,254 | +236.97% | ||
| 2023-12-12 | Zanganeh Mahkam | Chief Executive Officer | 5,000 0.0007% | $2.07 | $10,350 | +257.05% | ||
| 2023-10-13 | Soni Manmeet Singh | Chief Operating Officer | 2.98M 0.4265% | $1.68 | $5M | +163.99% | ||
| 2023-03-08 | Zanganeh Mahkam | Co-CEO & President | 23.53M 4.2977% | $1.05 | $24.7M | +26.97% | ||
| 2023-03-07 | Dhingra Ankur | Chief Financial Officer | 196,362 0.0395% | $1.05 | $206,180 | +39.86% | ||
| 2023-03-06 | DUGGAN ROBERT W | Chief Executive Officer | 376.49M 75.2052% | $1.05 | $395.31M | +38.49% | ||
| 2022-08-16 | DUGGAN ROBERT W | Chief Executive Officer | 94.85M 61.3078% | $0.97 | $92M | +70.30% | ||
| 2022-08-16 | Zanganeh Maky | Co-CEO & President | 1.03M 0.6664% | $0.97 | $999,997 | +70.30% | ||
| 2022-08-16 | Dhingra Ankur | Chief Financial Officer | 37,685 0.0244% | $0.97 | $36,554 | +70.30% | ||
| 2021-05-12 | DUGGAN ROBERT W | Chief Executive Officer | 11.37M 12.0109% | $5.24 | $59.56M | -6.40% | ||
| 2021-05-12 | Zanganeh Maky | Chief Operating Officer | 389,077 0.4112% | $5.24 | $2.04M | -6.40% | ||
| 2020-11-30 | Sale | Powell David Jonathan | Chief Scientific Officer | 13,713 0.0195% | $4.44 | $60,886 | +36.67% | |
| 2020-11-27 | Sale | Powell David Jonathan | Chief Scientific Officer | 29,569 0.043% | $4.39 | $129,808 | +41.94% | |
| 2020-11-25 | Sale | Powell David Jonathan | Chief Scientific Officer | 12,070 0.0175% | $4.32 | $52,142 | +43.93% | |
| 2020-11-24 | Sale | Powell David Jonathan | Chief Scientific Officer | 11,374 0.0164% | $4.21 | $47,885 | +46.08% | |
| 2020-11-23 | Sale | Powell David Jonathan | Chief Scientific Officer | 6,987 0.01% | $4.40 | $30,743 | +39.77% | |
| 2020-11-06 | DUGGAN ROBERT W | Chief Executive Officer | 14.07M 20.8007% | $3.34 | $47M | +89.54% |
Total: 20
Insider Historical Profitability
145.68%
| DUGGAN ROBERT W | Chief Executive Officer | 552354161 74.8827% | $10.65B | 4 | 0 | +47.98% |
| Zanganeh Mahkam | Chief Executive Officer | 24923800 3.3789% | $480.78M | 6 | 0 | +184.02% |
| Soni Manmeet Singh | Chief Operating Officer | 2976190 0.4035% | $57.41M | 1 | 0 | +163.99% |
| Dhingra Ankur | Chief Financial Officer | 354958 0.0481% | $6.85M | 4 | 0 | +181.3% |
Historical Insider Profitability vs. Competitors
$961,890,236 | 276 | 22.46% | $11.72B | |
$159,914,414 | 243 | 18.52% | $12.05B | |
$211,610,344 | 91 | 38.45% | $7.31B | |
$2,765,836 | 72 | 20.00% | $13.49B | |
$108,876,545 | 67 | 72.81% | $7.88B |
SMMT Institutional Investors: Active Positions
| Increased Positions | 146 | +98.65% | 13M | +15.65% |
| Decreased Positions | 62 | -41.89% | 5M | -5.38% |
| New Positions | 71 | New | 3M | New |
| Sold Out Positions | 25 | Sold Out | 2M | Sold Out |
| Total Postitions | 232 | +56.76% | 93M | +10.27% |
SMMT Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Baker Bros. Advisors Lp | $496,313.00 | 3.31% | 24.42M | 0 | 0% | 2024-12-31 |
| Vanguard Group Inc | $237,146.00 | 1.58% | 11.67M | +724,040 | +6.61% | 2024-12-31 |
| Blackrock, Inc. | $171,329.00 | 1.14% | 8.43M | +336,839 | +4.16% | 2024-12-31 |
| Fmr Llc | $163,685.00 | 1.09% | 8.06M | -247,749 | -2.98% | 2024-12-31 |
| Price T Rowe Associates Inc /Md/ | $133,257.00 | 0.89% | 6.56M | +1M | +20.56% | 2024-12-31 |
| State Street Corp | $113,851.00 | 0.76% | 5.6M | +2M | +61.54% | 2024-12-31 |
| Geode Capital Management, Llc | $65,041.00 | 0.43% | 3.2M | +101,039 | +3.26% | 2024-12-31 |
| Millennium Management Llc | $41,653.00 | 0.28% | 2.05M | +827,483 | +67.7% | 2024-12-31 |
| Charles Schwab Investment Management Inc | $30,177.00 | 0.2% | 1.49M | +52,359 | +3.65% | 2024-12-31 |
| Pictet Asset Management Holding Sa | $28,189.00 | 0.19% | 1.39M | +695,843 | +100.64% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.